Gautam Garima, Gogoi Sanjib, Saxena Sonal, Kaur Ravinder, Dhakad Megh Singh
Department of Microbiology, Lady Hardinge Medical College and Associated Hospitals, New Delhi, India.
Department of Microbiology, Maulana Azad Medical College and Associated Hospitals, New Delhi, India.
J Lab Physicians. 2021 Sep;13(3):252-256. doi: 10.1055/s-0041-1731106. Epub 2021 Jul 6.
Nitrofurantoin is the first-line drug in the treatment of uncomplicated urinary tract infections (UTIs) and its use has increased exponentially in recent years. This study aims to determine the susceptibility pattern of nitrofurantoin in gram-negative urinary isolates and to evaluate their bacteriological and epidemiological profile along with co-existing resistance to other important urinary antimicrobials. This was a retrospective study conducted in a tertiary care hospital in New Delhi in which 500 gram-negative bacterial urinary isolates were evaluated. Records of antimicrobial susceptibility were reviewed from July to September 2019. Antimicrobial susceptibility was performed using the Kirby-Bauer disk diffusion method on Mueller Hinton agar and interpreted using CLSI 2019. Test for extended spectrum β-lactamase (ESBL) producers was done using double disk approximation test. Data analysis was performed using the SPSS windows version 25.0 software. Out of total 500 isolates, 20.17% (94) isolates were resistant (R) to nitrofurantoin and 9.01% (42) were found to be intermediate (I). Highest resistance was seen in sp. (44.61%) and (8.12%). About 28.82% of the I/R isolates were of the pediatrics age group and most of the isolates belonged to females (64.69%). High resistance was also seen against ampicillin (92.30%), cefazolin (88.46%), ceftazidime (73.0%), and fluoroquinolones (65.38%). Carbapenemase co-resistance was seen in 57.15% isolates whereas ESBL production was seen in 30.76% of and 12.06% of sp. Increase in multidrug resistance uropathogens along with a near absence of novel oral antibiotics has led to increased consumption of nitrofurantoin since its resistance has increased.
呋喃妥因是治疗非复杂性尿路感染(UTIs)的一线药物,近年来其使用量呈指数级增长。本研究旨在确定革兰氏阴性尿分离株对呋喃妥因的敏感性模式,并评估其细菌学和流行病学特征以及对其他重要尿路抗菌药物的共存耐药性。这是一项在新德里一家三级护理医院进行的回顾性研究,其中评估了500株革兰氏阴性细菌尿分离株。回顾了2019年7月至9月的抗菌药物敏感性记录。使用Kirby-Bauer纸片扩散法在Mueller Hinton琼脂上进行抗菌药物敏感性试验,并根据CLSI 2019进行解释。使用双纸片协同试验检测超广谱β-内酰胺酶(ESBL)产生菌。使用SPSS windows版本25.0软件进行数据分析。在总共500株分离株中,20.17%(94株)对呋喃妥因耐药(R),9.01%(42株)为中介(I)。在[具体菌种1](44.61%)和[具体菌种2](8.12%)中观察到最高耐药率。约28.82%的中介/耐药分离株属于儿科年龄组,大多数分离株为女性(64.69%)。对氨苄西林(92.30%)、头孢唑林(88.46%)、头孢他啶(73.0%)和氟喹诺酮类(65.38%)也观察到高耐药率。57.15%的分离株存在碳青霉烯酶共存耐药,而30.76%的[具体菌种3]和12.06%的[具体菌种4]产生ESBL。多重耐药尿路病原体增加以及几乎没有新型口服抗生素,导致自呋喃妥因耐药性增加以来其消耗量增加。